Pseudomyxoma peritonei

Cancer Treat Rev. 2007 Apr;33(2):138-45. doi: 10.1016/j.ctrv.2006.11.001. Epub 2006 Dec 19.

Abstract

Pseudomyxoma peritonei (PMP) is a rare condition, which is known for its high mortality when not treated properly. The first step to improve prognosis of these patients is to recognize this clinical syndrome preferably in an early stage. Knowledge of pathogenesis and common diagnostic tools is essential in this regard. Treatment strategy for PMP should pursue complete cytoreduction and prevention of recurrence or progression. Combined modality treatment, consisting of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy, seems very efficient in this regard. This approach is currently carried out in many centers throughout the world with promising results and seems to win ground as the standard treatment approach.

Publication types

  • Review

MeSH terms

  • Combined Modality Therapy
  • Humans
  • Peritoneal Neoplasms* / diagnosis
  • Peritoneal Neoplasms* / therapy
  • Pseudomyxoma Peritonei* / diagnosis
  • Pseudomyxoma Peritonei* / therapy